Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
MGNX's Cash to Debt is ranked higher than
75% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MGNX' s Cash to Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity to Asset 0.90
MGNX's Equity to Asset is ranked higher than
84% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MGNX: 0.90 )
Ranked among companies with meaningful Equity to Asset only.
MGNX' s Equity to Asset Range Over the Past 10 Years
Min: -0.26  Med: 0.72 Max: 0.9
Current: 0.9
-0.26
0.9
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
64% of the 464 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 2
Z-Score: 16.64
M-Score: 13.27
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -32.49
MGNX's Operating margin (%) is ranked higher than
60% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. MGNX: -32.49 )
Ranked among companies with meaningful Operating margin (%) only.
MGNX' s Operating margin (%) Range Over the Past 10 Years
Min: -80.16  Med: 0.63 Max: 12.86
Current: -32.49
-80.16
12.86
Net-margin (%) -31.77
MGNX's Net-margin (%) is ranked higher than
59% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. MGNX: -31.77 )
Ranked among companies with meaningful Net-margin (%) only.
MGNX' s Net-margin (%) Range Over the Past 10 Years
Min: -80.16  Med: -0.45 Max: 13.1
Current: -31.77
-80.16
13.1
ROE (%) -11.41
MGNX's ROE (%) is ranked higher than
67% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. MGNX: -11.41 )
Ranked among companies with meaningful ROE (%) only.
MGNX' s ROE (%) Range Over the Past 10 Years
Min: -38.27  Med: -9.27 Max: -0.74
Current: -11.41
-38.27
-0.74
ROA (%) -9.99
MGNX's ROA (%) is ranked higher than
66% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. MGNX: -9.99 )
Ranked among companies with meaningful ROA (%) only.
MGNX' s ROA (%) Range Over the Past 10 Years
Min: -25.57  Med: -0.29 Max: 14.36
Current: -9.99
-25.57
14.36
ROC (Joel Greenblatt) (%) -131.20
MGNX's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. MGNX: -131.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MGNX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -648.31  Med: 8.82 Max: 250.31
Current: -131.2
-648.31
250.31
» MGNX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MGNX Guru Trades in Q3 2015

Jim Simons 26,224 sh (New)
Julian Robertson 403,275 sh (+21.00%)
First Eagle Investment 403,181 sh (+2.54%)
Ronald Muhlenkamp 66,500 sh (unchged)
John Griffin 1,350,000 sh (unchged)
George Soros 19,488 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 2,530,700 sh (-0.64%)
» More
Q4 2015

MGNX Guru Trades in Q4 2015

Jim Simons 92,664 sh (+253.36%)
Julian Robertson 575,129 sh (+42.61%)
George Soros 19,488 sh (unchged)
John Griffin 1,350,000 sh (unchged)
Ronald Muhlenkamp 66,410 sh (-0.14%)
Steven Cohen 2,111,876 sh (-16.55%)
First Eagle Investment 290,000 sh (-28.07%)
» More
Q1 2016

MGNX Guru Trades in Q1 2016

Steven Cohen 2,330,200 sh (+10.34%)
Ronald Muhlenkamp 67,245 sh (+1.26%)
John Griffin 1,360,000 sh (+0.74%)
George Soros 19,488 sh (unchged)
Julian Robertson 575,129 sh (unchged)
First Eagle Investment 285,800 sh (-1.45%)
Jim Simons 20,723 sh (-77.64%)
» More
Q2 2016

MGNX Guru Trades in Q2 2016

Paul Tudor Jones 12,858 sh (New)
Steven Cohen 2,554,900 sh (+9.64%)
John Griffin 1,360,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
First Eagle Investment 221,800 sh (-22.39%)
Julian Robertson 313,140 sh (-45.55%)
Ronald Muhlenkamp 15,835 sh (-76.45%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:RGEN, OTCPK:BVNKF, NAS:PTLA, OTCPK:MPSYY, NAS:XLRN, NAS:FOLD, NAS:DERM, NYSE:EBS, NAS:INSY, NAS:ACOR, NAS:ADRO, NAS:BGNE, NAS:FGEN, NAS:SAGE, NAS:CEMP, NAS:FWP, NAS:AVXS, NAS:ACHN, NAS:CLLS, NAS:SRPT » details
Traded in other countries:M55.Germany,
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc was incorporated in Delaware on August 14, 2000. The Company is a clinical-stage biopharmaceutical company, engaged in discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The Company currently has a manufacturing facility located in Rockville, Maryland. The Company has three versatile, proprietary technology platforms consisting of: its Dual Affinity Re-Targeting ("DART") platform, which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient's body to destroy targeted cancer cells; its Fc Optimization platform, which enhances the body's immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity ("ADCC") in which antibodies and immune cells cooperate to destroy targets such as tumor cells; and its Cancer Stem-like Cell ("CSLC") platform, which provides a discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them. It currently has two oncology product candidates in clinical development. The product candidates are subject to regulation in the United States by the Food and Drug Administration as biological products.

Ratios

vs
industry
vs
history
P/B 3.35
MGNX's P/B is ranked higher than
55% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. MGNX: 3.35 )
Ranked among companies with meaningful P/B only.
MGNX' s P/B Range Over the Past 10 Years
Min: 1.73  Med: 3.95 Max: 12.83
Current: 3.35
1.73
12.83
P/S 10.54
MGNX's P/S is ranked higher than
53% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. MGNX: 10.54 )
Ranked among companies with meaningful P/S only.
MGNX' s P/S Range Over the Past 10 Years
Min: 1.12  Med: 8.6 Max: 24.45
Current: 10.54
1.12
24.45
Current Ratio 17.84
MGNX's Current Ratio is ranked higher than
91% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. MGNX: 17.84 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.04 Max: 17.84
Current: 17.84
1.35
17.84
Quick Ratio 17.84
MGNX's Quick Ratio is ranked higher than
91% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MGNX: 17.84 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.35  Med: 7.04 Max: 17.84
Current: 17.84
1.35
17.84
Days Sales Outstanding 268.92
MGNX's Days Sales Outstanding is ranked lower than
93% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. MGNX: 268.92 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.43  Med: 12.6 Max: 268.92
Current: 268.92
4.43
268.92

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.86
MGNX's Price/Net Cash is ranked higher than
59% of the 515 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. MGNX: 4.86 )
Ranked among companies with meaningful Price/Net Cash only.
MGNX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.29  Med: 4.62 Max: 9.94
Current: 4.86
2.29
9.94
Price/Net Current Asset Value 3.57
MGNX's Price/Net Current Asset Value is ranked higher than
70% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. MGNX: 3.57 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MGNX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.25  Med: 4.38 Max: 9.52
Current: 3.57
2.25
9.52
Price/Tangible Book 3.34
MGNX's Price/Tangible Book is ranked higher than
62% of the 764 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. MGNX: 3.34 )
Ranked among companies with meaningful Price/Tangible Book only.
MGNX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.16  Med: 4.17 Max: 8.75
Current: 3.34
2.16
8.75
Price/Median PS Value 1.22
MGNX's Price/Median PS Value is ranked lower than
64% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MGNX: 1.22 )
Ranked among companies with meaningful Price/Median PS Value only.
MGNX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.14  Med: 1.04 Max: 2.32
Current: 1.22
0.14
2.32
Earnings Yield (Greenblatt) (%) -4.10
MGNX's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. MGNX: -4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MGNX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.3  Med: 0.2 Max: 1.5
Current: -4.1
-4.3
1.5

More Statistics

Revenue (TTM) (Mil) $106.4
EPS (TTM) $ -1.12
Short Percentage of Float8.50%
52-Week Range $14.84 - 36.11
Shares Outstanding (Mil)34.73

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 114 60 56
EPS ($) -1.29 -3.55 -3.78
EPS w/o NRI ($) -1.29 -3.55 -3.78
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple Aug 15 2016 
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MACROGENICS INC Financials Aug 10 2016
ETF’s with exposure to MacroGenics, Inc. : August 8, 2016 Aug 08 2016
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 5, 2016 Aug 05 2016
MacroGenics downgraded by Citigroup Aug 04 2016
MacroGenics to Participate in Two Upcoming Investor Conferences Aug 04 2016
MacroGenics to Participate in Two Upcoming Investor Conferences Aug 04 2016
Edited Transcript of MGNX earnings conference call or presentation 3-Aug-16 8:30pm GMT Aug 03 2016
MacroGenics beats Street 2Q forecasts Aug 03 2016
MacroGenics beats Street 2Q forecasts Aug 03 2016
MACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 03 2016
MacroGenics Provides Update on Corporate Progress and Second Quarter 2016 Financial Results Aug 03 2016
Q2 2016 MacroGenics Inc Earnings Release - After Market Close Aug 03 2016
Medical Product Stocks Earnings Preview for Aug 3: BIO, CSII & More Aug 02 2016
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call Jul 27 2016
MacroGenics Announces Date of Second Quarter 2016 Financial Results Conference Call Jul 27 2016
MacroGenics Announces Closing of Collaboration and License Agreement with Janssen to Develop MGD015 Jun 28 2016
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology... Jun 10 2016
MacroGenics Presents Data from Phase 1 Study of MGD010 at Annual European Congress of Rheumatology... Jun 10 2016
MACROGENICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 20 2016
MacroGenics scores drug licensing deal worth up to $740 million May 19 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)